Latest Update: Impact of current COVID-19 situation has been considered in this report while making the analysis.
Global Drugs for Herpes Labialis (Oral Herpes) Market by Type (Aciclovir, Valacyclovir, Famciclovir, Docosanol, Other), By Application (External Use, Oral, Injection) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030-report

Global Drugs for Herpes Labialis (Oral Herpes) Market by Type (Aciclovir, Valacyclovir, Famciclovir, Docosanol, Other), By Application (External Use, Oral, Injection) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030

Report ID: 309085 4200 Pharma & Healthcare 377 158 Pages 4.7 (40)
                                          

Industry Growth Insights published a new data on “Drugs for Herpes Labialis (Oral Herpes) Market”. The research report is titled “Drugs for Herpes Labialis (Oral Herpes) Market research by Types (Aciclovir, Valacyclovir, Famciclovir, Docosanol, Other), By Applications (External Use, Oral, Injection), By Players/Companies GSK, Novartis, Teva, Mylan, Cadila, Apotex, Daewoong Pharmaceutical, Livzon, Luoxin, Med shine, Bayer (Campho Phenique), Blistex, Kelun, Hikma, Haiwang, Carmex, Cipher”.

Scope Of The Report

Report Attributes

Report Details

Report Title

Drugs for Herpes Labialis (Oral Herpes) Market Research Report

By Type

Aciclovir, Valacyclovir, Famciclovir, Docosanol, Other

By Application

External Use, Oral, Injection

By Companies

GSK, Novartis, Teva, Mylan, Cadila, Apotex, Daewoong Pharmaceutical, Livzon, Luoxin, Med shine, Bayer (Campho Phenique), Blistex, Kelun, Hikma, Haiwang, Carmex, Cipher

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year

2021

Historical Year

2019 to 2020 (Data from 2010 can be provided as per availability)

Forecast Year

2030

Number of Pages

158

Number of Tables & Figures

111

Customization Available

Yes, the report can be customized as per your need.


Global Drugs for Herpes Labialis (Oral Herpes) Industry Outlook


Global Drugs for Herpes Labialis (Oral Herpes) Market Report Segments:

The global Drugs for Herpes Labialis (Oral Herpes) market is segmented on the basis of:

Types

Aciclovir, Valacyclovir, Famciclovir, Docosanol, Other

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.

Applications

External Use, Oral, Injection

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

  1. GSK
  2. Novartis
  3. Teva
  4. Mylan
  5. Cadila
  6. Apotex
  7. Daewoong Pharmaceutical
  8. Livzon
  9. Luoxin
  10. Med shine
  11. Bayer (Campho Phenique)
  12. Blistex
  13. Kelun
  14. Hikma
  15. Haiwang
  16. Carmex
  17. Cipher

Global Drugs for Herpes Labialis (Oral Herpes) Market Overview


Highlights of The Drugs for Herpes Labialis (Oral Herpes) Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2030.
  5. Developments and trends in the market.
  6. By Type:

    1. Aciclovir
    2. Valacyclovir
    3. Famciclovir
    4. Docosanol
    5. Other
  1. By Application:

    1. External Use
    2. Oral
    3. Injection
  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Drugs for Herpes Labialis (Oral Herpes) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.

Regional Analysis

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Global Drugs for Herpes Labialis (Oral Herpes) Market Statistics

8 Reasons to Buy This Report

  1. Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
  2. Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
  3. Implemented Robust Methodology to Prepare the Report
  4. Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
  5. Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
  6. Provides Information About the Top-winning Strategies Implemented by Industry Players.
  7. In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
  8. Customization of the Report Available

Frequently Asked Questions?


Drugs for Herpes Labialis (Oral Herpes) are medications that help to treat the symptoms of herpes simplex virus (HSV) infection, such as fever, pain, and itching. These drugs can also help to prevent new episodes of herpes. Some common drugs used to treat oral herpes include acyclovir (Zovirax), famciclovir (Famvir), and valacyclovir (Valtrex).

Some of the major players in the drugs for herpes labialis (oral herpes) market are GSK, Novartis, Teva, Mylan, Cadila, Apotex, Daewoong Pharmaceutical, Livzon, Luoxin, Med shine, Bayer (Campho Phenique), Blistex, Kelun, Hikma, Haiwang, Carmex, Cipher.

                                            
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Drugs for Herpes Labialis (Oral Herpes) Market Overview    4.1 Introduction       4.1.1 Market Taxonomy       4.1.2 Market Definition       4.1.3 Macro-Economic Factors Impacting the Market Growth    4.2 Drugs for Herpes Labialis (Oral Herpes) Market Dynamics       4.2.1 Market Drivers       4.2.2 Market Restraints       4.2.3 Market Opportunity    4.3 Drugs for Herpes Labialis (Oral Herpes) Market - Supply Chain Analysis       4.3.1 List of Key Suppliers       4.3.2 List of Key Distributors       4.3.3 List of Key Consumers    4.4 Key Forces Shaping the Drugs for Herpes Labialis (Oral Herpes) Market       4.4.1 Bargaining Power of Suppliers       4.4.2 Bargaining Power of Buyers       4.4.3 Threat of Substitution       4.4.4 Threat of New Entrants       4.4.5 Competitive Rivalry    4.5 Global Drugs for Herpes Labialis (Oral Herpes) Market Size & Forecast, 2020-2028       4.5.1 Drugs for Herpes Labialis (Oral Herpes) Market Size and Y-o-Y Growth       4.5.2 Drugs for Herpes Labialis (Oral Herpes) Market Absolute $ Opportunity

Chapter 5 Global  Market Analysis and Forecast by Type
   5.1 Introduction
      5.1.1 Key Market Trends & Growth Opportunities by Type
      5.1.2 Basis Point Share (BPS) Analysis by Type
      5.1.3 Absolute $ Opportunity Assessment by Type
   5.2  Market Size Forecast by Type
      5.2.1 Aciclovir
      5.2.2 Valacyclovir
      5.2.3 Famciclovir
      5.2.4 Docosanol
      5.2.5 Other
   5.3 Market Attractiveness Analysis by Type

Chapter 6 Global  Market Analysis and Forecast by Applications
   6.1 Introduction
      6.1.1 Key Market Trends & Growth Opportunities by Applications
      6.1.2 Basis Point Share (BPS) Analysis by Applications
      6.1.3 Absolute $ Opportunity Assessment by Applications
   6.2  Market Size Forecast by Applications
      6.2.1 External Use
      6.2.2 Oral
      6.2.3 Injection
   6.3 Market Attractiveness Analysis by Applications

Chapter 7 Global Drugs for Herpes Labialis (Oral Herpes) Market Analysis and Forecast by Region
   7.1 Introduction
      7.1.1 Key Market Trends & Growth Opportunities by Region
      7.1.2 Basis Point Share (BPS) Analysis by Region
      7.1.3 Absolute $ Opportunity Assessment by Region
   7.2 Drugs for Herpes Labialis (Oral Herpes) Market Size Forecast by Region
      7.2.1 North America
      7.2.2 Europe
      7.2.3 Asia Pacific
      7.2.4 Latin America
      7.2.5 Middle East & Africa (MEA)
   7.3 Market Attractiveness Analysis by Region

Chapter 8 Coronavirus Disease (COVID-19) Impact 
   8.1 Introduction 
   8.2 Current & Future Impact Analysis 
   8.3 Economic Impact Analysis 
   8.4 Government Policies 
   8.5 Investment Scenario

Chapter 9 North America  Analysis and Forecast
   9.1 Introduction
   9.2 North America  Market Size Forecast by Country
      9.2.1 U.S.
      9.2.2 Canada
   9.3 Basis Point Share (BPS) Analysis by Country
   9.4 Absolute $ Opportunity Assessment by Country
   9.5 Market Attractiveness Analysis by Country
   9.6 North America  Market Size Forecast by Type
      9.6.1 Aciclovir
      9.6.2 Valacyclovir
      9.6.3 Famciclovir
      9.6.4 Docosanol
      9.6.5 Other
   9.7 Basis Point Share (BPS) Analysis by Type 
   9.8 Absolute $ Opportunity Assessment by Type 
   9.9 Market Attractiveness Analysis by Type
   9.10 North America  Market Size Forecast by Applications
      9.10.1 External Use
      9.10.2 Oral
      9.10.3 Injection
   9.11 Basis Point Share (BPS) Analysis by Applications 
   9.12 Absolute $ Opportunity Assessment by Applications 
   9.13 Market Attractiveness Analysis by Applications

Chapter 10 Europe  Analysis and Forecast
   10.1 Introduction
   10.2 Europe  Market Size Forecast by Country
      10.2.1 Germany
      10.2.2 France
      10.2.3 Italy
      10.2.4 U.K.
      10.2.5 Spain
      10.2.6 Russia
      10.2.7 Rest of Europe
   10.3 Basis Point Share (BPS) Analysis by Country
   10.4 Absolute $ Opportunity Assessment by Country
   10.5 Market Attractiveness Analysis by Country
   10.6 Europe  Market Size Forecast by Type
      10.6.1 Aciclovir
      10.6.2 Valacyclovir
      10.6.3 Famciclovir
      10.6.4 Docosanol
      10.6.5 Other
   10.7 Basis Point Share (BPS) Analysis by Type 
   10.8 Absolute $ Opportunity Assessment by Type 
   10.9 Market Attractiveness Analysis by Type
   10.10 Europe  Market Size Forecast by Applications
      10.10.1 External Use
      10.10.2 Oral
      10.10.3 Injection
   10.11 Basis Point Share (BPS) Analysis by Applications 
   10.12 Absolute $ Opportunity Assessment by Applications 
   10.13 Market Attractiveness Analysis by Applications

Chapter 11 Asia Pacific  Analysis and Forecast
   11.1 Introduction
   11.2 Asia Pacific  Market Size Forecast by Country
      11.2.1 China
      11.2.2 Japan
      11.2.3 South Korea
      11.2.4 India
      11.2.5 Australia
      11.2.6 South East Asia (SEA)
      11.2.7 Rest of Asia Pacific (APAC)
   11.3 Basis Point Share (BPS) Analysis by Country
   11.4 Absolute $ Opportunity Assessment by Country
   11.5 Market Attractiveness Analysis by Country
   11.6 Asia Pacific  Market Size Forecast by Type
      11.6.1 Aciclovir
      11.6.2 Valacyclovir
      11.6.3 Famciclovir
      11.6.4 Docosanol
      11.6.5 Other
   11.7 Basis Point Share (BPS) Analysis by Type 
   11.8 Absolute $ Opportunity Assessment by Type 
   11.9 Market Attractiveness Analysis by Type
   11.10 Asia Pacific  Market Size Forecast by Applications
      11.10.1 External Use
      11.10.2 Oral
      11.10.3 Injection
   11.11 Basis Point Share (BPS) Analysis by Applications 
   11.12 Absolute $ Opportunity Assessment by Applications 
   11.13 Market Attractiveness Analysis by Applications

Chapter 12 Latin America  Analysis and Forecast
   12.1 Introduction
   12.2 Latin America  Market Size Forecast by Country
      12.2.1 Brazil
      12.2.2 Mexico
      12.2.3 Rest of Latin America (LATAM)
   12.3 Basis Point Share (BPS) Analysis by Country
   12.4 Absolute $ Opportunity Assessment by Country
   12.5 Market Attractiveness Analysis by Country
   12.6 Latin America  Market Size Forecast by Type
      12.6.1 Aciclovir
      12.6.2 Valacyclovir
      12.6.3 Famciclovir
      12.6.4 Docosanol
      12.6.5 Other
   12.7 Basis Point Share (BPS) Analysis by Type 
   12.8 Absolute $ Opportunity Assessment by Type 
   12.9 Market Attractiveness Analysis by Type
   12.10 Latin America  Market Size Forecast by Applications
      12.10.1 External Use
      12.10.2 Oral
      12.10.3 Injection
   12.11 Basis Point Share (BPS) Analysis by Applications 
   12.12 Absolute $ Opportunity Assessment by Applications 
   12.13 Market Attractiveness Analysis by Applications

Chapter 13 Middle East & Africa (MEA)  Analysis and Forecast
   13.1 Introduction
   13.2 Middle East & Africa (MEA)  Market Size Forecast by Country
      13.2.1 Saudi Arabia
      13.2.2 South Africa
      13.2.3 UAE
      13.2.4 Rest of Middle East & Africa (MEA)
   13.3 Basis Point Share (BPS) Analysis by Country
   13.4 Absolute $ Opportunity Assessment by Country
   13.5 Market Attractiveness Analysis by Country
   13.6 Middle East & Africa (MEA)  Market Size Forecast by Type
      13.6.1 Aciclovir
      13.6.2 Valacyclovir
      13.6.3 Famciclovir
      13.6.4 Docosanol
      13.6.5 Other
   13.7 Basis Point Share (BPS) Analysis by Type 
   13.8 Absolute $ Opportunity Assessment by Type 
   13.9 Market Attractiveness Analysis by Type
   13.10 Middle East & Africa (MEA)  Market Size Forecast by Applications
      13.10.1 External Use
      13.10.2 Oral
      13.10.3 Injection
   13.11 Basis Point Share (BPS) Analysis by Applications 
   13.12 Absolute $ Opportunity Assessment by Applications 
   13.13 Market Attractiveness Analysis by Applications

Chapter 14 Competition Landscape 
   14.1 Drugs for Herpes Labialis (Oral Herpes) Market: Competitive Dashboard
   14.2 Global Drugs for Herpes Labialis (Oral Herpes) Market: Market Share Analysis, 2019
   14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.3.1 GSK
      14.3.2 Novartis
      14.3.3 Teva
      14.3.4 Mylan
      14.3.5 Cadila
      14.3.6 Apotex
      14.3.7 Daewoong Pharmaceutical
      14.3.8 Livzon
      14.3.9 Luoxin
      14.3.10 Med shine
      14.3.11 Bayer (Campho Phenique)
      14.3.12 Blistex
      14.3.13 Kelun
      14.3.14 Hikma
      14.3.15 Haiwang
      14.3.16 Carmex
      14.3.17 Cipher

Our Trusted Clients

Contact Us